Absci Quarterly Income Statement
NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Absci revenue and earnings
In the quarter ended Jun 30, 2026, Absci generated $318,000 in revenue, down 46.4% from the same quarter a year earlier. Absci reported a net loss of $33.2 million, compared with a loss of $30.6 million a year earlier. Operating margin was -10741.5%.
Diluted earnings per share came in at -$0.21.
Summary generated from market data by MetaCap's automated system. Methodology
Absci income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 318.00K | 215.00K | 650.00K | 378.00K | 593.00K | 1.18M | 665.00K | 1.70M | 1.27M | 898.00K | 338.00K | 744.00K |
| Revenue growth (YoY) | -46.37% | -81.76% | -2.26% | -77.78% | -53.31% | +31.29% | +96.75% | +128.63% | -62.28% | -29.24% | -78.29% | -68.59% |
| Operating Expenses | 34.48M | 31.06M | 31.69M | 30.53M | 31.99M | 28.91M | 30.44M | 30.60M | 27.99M | 24.40M | 25.08M | 24.05M |
| Research & Development | 22.62M | 19.27M | 25.35M | 19.25M | 20.46M | 16.36M | 18.38M | 17.98M | 15.26M | 12.24M | 12.27M | 11.03M |
| Selling, General & Admin | 9.16M | 9.06M | 8.62M | 8.44M | 8.53M | 9.47M | 8.83M | 9.26M | 9.35M | 8.74M | 9.32M | 9.51M |
| Operating Income | -34.16M | -30.85M | -31.04M | -30.15M | -31.39M | -27.73M | -29.77M | -28.89M | -26.72M | -23.50M | -24.74M | -23.30M |
| Interest Expense | 2.00K | 18.00K | 29.00K | 45.00K | 56.00K | 79.00K | 109.00K | 130.00K | 150.00K | 176.00K | 204.00K | 229.00K |
| Other Income (Expense) | 988.00K | 1.26M | 1.32M | 1.55M | 955.00K | 1.38M | 812.00K | 1.53M | 1.97M | 1.53M | 1.24M | 1.34M |
| Pretax Income | -33.17M | -29.58M | -29.72M | -28.60M | -30.44M | -26.35M | -28.96M | -27.36M | -24.75M | -21.96M | -23.50M | -21.96M |
| Income Tax | 40.00K | 18.00K | -162.00K | 104.00K | 131.00K | -4.00K | 21.00K | 37.00K | 0 | 12.00K | 48.00K | 34.00K |
| Net Income | -33.21M | -29.60M | -29.56M | -28.71M | -30.57M | -26.35M | -28.98M | -27.40M | -24.75M | -21.98M | -23.55M | -21.99M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.21 | -0.19 | -0.19 | -0.20 | -0.24 | -0.21 | -0.26 | -0.24 | -0.22 | -0.22 | -0.25 | -0.24 |
| EPS (Diluted) | -0.21 | -0.19 | -0.19 | -0.20 | -0.24 | -0.21 | -0.26 | -0.24 | -0.22 | -0.22 | -0.25 | -0.24 |
| Shares Outstanding (Basic) | 157.47M | 152.96M | — | 143.77M | 127.59M | 124.46M | — | 113.61M | 112.93M | 99.39M | — | 92.22M |
| Shares Outstanding (Diluted) | 157.47M | 152.96M | — | 143.77M | 127.59M | 124.46M | — | 113.61M | 112.93M | 99.39M | — | 92.22M |
| EBITDA | -31.46M | -28.12M | -28.21M | -27.31M | -28.39M | -24.66M | -26.54M | -25.54M | -23.34M | -20.08M | -21.25M | -19.79M |
| Operating Margin | -10741.51% | -14346.98% | -4775.54% | -7977.25% | -5293.93% | -2351.91% | -4477.29% | -1698.71% | -2104.02% | -2616.70% | -7319.23% | -3132.12% |
| Net Margin | -10443.40% | -13766.98% | -4548.00% | -7594.18% | -5154.97% | -2234.61% | -4358.35% | -1610.70% | -1948.82% | -2447.10% | -6965.98% | -2956.18% |
This table shows 12 quarterly periods of Absci's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ABSI's reporting calendar. What is a income statement?